Canadian Pharma, Biotech and Life Sciences Stocks

Promis Neurosciences could have a groundbreaking Alzheimer’s treatment, Mackie Research says

Promis Neurosciences (TSX:PMN) is sitting on an Alzheimer’s drug candidate that could prove to be best-in-class, says Mackie Research Capital analyst André Uddin. In a research report to clients today, Uddin inititated coverage of Promis Neurosciences with a “Speculative Buy” rating and one- ...

ProMetic Life Sciences has 197% upside, says Canaccord Genuity

Prometic Life Sciences CEO Pierre Laurin New data from ProMetic Life Sciences’ (TSX:PLI) ongoing phase 2 open-label clinical trial is giving Canaccord Genuity analyst Neil Maruoka more confidence in his bullish target on the stock. This morning, ProMetic reported what it described as positive c ...

Anthony Giovinazzo Receives the 2017 Bloom Burton Award

Anthony Giovinazzo Receives the 2017 Bloom Burton Award TORONTO, September 19, 2017 – Bloom Burton & Co. (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce Anthony Giovinazzo as the recipient of the inaugural Bloom Burton Award. Mr. G ...

Canaccord Genuity raises price target on Oncolytics Biotech to $2.50

Oncolytics Biotech CEO Matt Coffey The end of Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) phase two meetings with the FDA have derisked the story, says Canaccord Genuity analyst Neil Maruoka. This morning, Oncolytics Biotech announced it had completed the successful end of its phase two meeting wit ...

Organigram Holdings is still undervalued, says GMP

A supply agreement with the province of New Brunwick is a strong vote of confidence in Organigram (TSXV:OGI), says GMP Securities analyst Martin Landry. On Friday, Organigram announced it had entered into a memorandum of understanding with the province of New Brunswick that will see the former sup ...

New Brunswick news doesn’t move the needle for Canopy Growth, says Canaccord Genuity

Canopy Growth Corp. CEO Bruce Linton. A supply deal with the province of New Brunswick isn’t changing Canaccord Genuity analyst Neil Maruoka’s mind about Canopy Growth Corp. (TSX:WEED), which he feels is fully valued. This morning, Canopy Growth announced it had signed a two-year supply agree ...

TSO3 has regulatory winds at its back, says Canaccord Genuity

Recent regulatory and industry developments are putting the wind at the back of TSO3 (TSX:TOS), says Canaccord Genuity analyst Neil Maruoka. Recently, the Association for the Advancement of Medical Instrumentation reported conclusions from a stakeholder meeting that included representation from th ...

Canopy Growth Corp is looking fully valued: Canaccord Genuity

Canopy Growth CEO Bruce Linton Recent expansion plans underscore the very plausible idea that Canopy Growth Corp. (TSX:WEED) will be one of the winners in the marijuana sector, but the stock is looking pricey, says Canaccord Genuity analyst Neil Maruoka. On September 8, Canopy announced it had fi ...

Mackie Research lowers price target on Cardiome Pharma

The licensing of a new product isn’t enough for Mackie Research Capital analyst André Uddin to maintain his enthusiasm for Cardiome Pharma (TSX:COM, Nasdaq:CRME) in the face of falling comparables. This morning, Cardiome announced it had reached an agreement with Basilea to distribute and licen ...